<DOC>
	<DOCNO>NCT00896532</DOCNO>
	<brief_summary>This phase 2 clinical trial study safety efficacy AMG 785 , investigational bone building agent , treatment postmenopausal woman low bone mineral density . Different dos dose frequency AMG 785 compare placebo double-blind fashion . In addition , AMG 785 compare open label alendronate open label teriparatide . The clinical hypothesis AMG 785 compare placebo cause great percent change baseline lumbar spine bone mineral density . At end initial 24 month treatment phase , eligible subject enter 12 month extension phase . Subjects randomize 1:1 within original treatment group receive either denosumab placebo every 6 month Subjects participate 12 month extension phase follow additional three month Month 27 . At end 12 month extension phase , eligible subject enter 12 month retreatment phase . All subject participate re-treatment phase receive 210 mg AMG 785 QM 12 month . Subjects participate 12 month re-treatment phase complete study Month 36 . At end 12 month AMG 785 retreatment phase , subject enter 24 month follow-on phase . Based outcome eligibility assessment , subject either receive one dose 5 mg ZOL intravenously intervention . Subjects participate 24 month follow-on phase follow additional 3 month observational period month 51 .</brief_summary>
	<brief_title>Phase 2 Study AMG 785 Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Ambulatory , postmenopausal woman , age ≥ 55 ≤ 85 Low BMD measure Dual energy Xray Absorptiometry ( DXA ) assess central image vendor ( equivalent Tscores 2.0 3.5 ) History vertebral fracture , fragility fracture wrist , humerus , hip pelvis age 50 Untreated hyper hypothyroidism Current hyper hypoparathyroidism , hypo hypercalcemia Elevated transaminases Significantly impaired renal function Positive : HIV , HepC HepB surface antigen Malignancy History solid organ bone marrow transplant Use agent affect bone metabolism Contraindicated intolerant alendronate therapy Contraindicated intolerant teriparatide therapy Inclusion Criteria 12 month extension phase ( Month 24 36 ) : Normocalcemia Month 21 visit Month 24 study visit Exclusion Criteria 12 month extension phase ( Month 24 36 ) Incidence clinical vertebral fracture fragility fracture wrist , humerus , hip pelvis initial 24 month treatment phase study A BMD loss ≥ 7.0 % baseline time Month 18 visit initial 24month treatment phase Malignancy History osteonecrosis jaw Use proscribe medication initial 24 month treatment phase Contraindicated intolerant denosumab therapy Inclusion Criteria 12 month retreatment phase ( Month 36 48 ) albumin adjust serum calcium recent blood draw Month 30 visit Month 36 study visit . Calcium repletion permit central laboratory analysis albumin adjust serum calcium may repeat Month 36 study visit Participation Group A B initial 24 month treatment phase Subject reach M36 study Appropriate write informed consent must obtain Exclusion Criteria 12 month retreatment phase ( Month 36 48 ) New malignancy Use proscribe medication 12 month extension phase Inclusion Criteria 24 month followon phase ( Month 48 72 ) General inclusion criterion participation Subject reach month 48 study Appropriate write ICF must obtain Inclusion criterion assignment intervention group During 24 month AMG 785 treatment phase , subject assign AMG 785 treatment group During 12 month denosumab extension phase , subject assign denosumab treatment group Exclusion 24 month followon phase ( Month 48 72 ) New malignancy Use proscribe med 12 month retreatment phase Partial ICF withdrawal discontinuation IP time month 48 visit Incidence clinical vertebral fracture fragility fracture wrist , humerus , hip pelvis initial 24 month treatment phase study BMD Tscore ≤ 2.5 lumbar spine , total hip , femoral neck base local read DXA scan month 48 Intolerance Zoledronic acid</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>